There are now five commercially available tyrosine kinase inhibitors for the treatment of Ph+ CML: imatinib, dasatinib, nilotinib, bosutinib, and ponatinib; of these, dasatinib and bosutinib (Figure 6) are dual SRC-ABL inhibitors [96]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.